CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
rivastigmine transdermal patchdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00099242
NCT00099242Phase 3Completed
CompareCT.gov

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Novartis Pharmaceuticals·interventional·Posted Dec 10, 2004·Updated Oct 13, 2017

In Brief

A Phase 3 clinical trial evaluating rivastigmine transdermal patch for Alzheimer's Disease and Dementia, Alzheimer Type. Completed, across 75 sites in 21 countries.

Detailed Summary

The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Dementia, Alzheimer Type
CountriesChile, Czechia, Denmark, Finland, Germany, Guatemala, Israel, Italy, Mexico, Norway, Peru, Poland, Portugal, Puerto Rico, Russia, Slovakia, South Korea, Sweden, Taiwan, United States, Venezuela
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 10, 2004
Enrollment StartNov 1, 2003
Study CompletionJan 1, 2006
TodayJul 2, 2026
Posted 21.6 years ago

Interventions

rivastigmine transdermal patchdrug